Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018
22 Décembre 2017 - 2:00PM
Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that
it will host an investor event to discuss expected corporate and
product milestones in 2018. The event is scheduled to take place on
Tuesday, January 9, at 7 a.m. PT (10 a.m. ET) and will be
simultaneously webcast.
Portola will provide clinical, regulatory and manufacturing
updates on the Company’s first FDA-approved product, betrixaban,
and its two investigational hematologic compounds – the
anticoagulant reversal agent andexanet alfa and the oral, dual
Syk/JAK kinase inhibitor cerdulatinib.
Webcast DetailsTo access the live investor
webcast on Tuesday, January 9 at 7 a.m. PT (10 a.m. ET), go to the
Investor Relations section of the company’s website at
http://investors.portola.com. A replay will be available for 30
days.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company’s
first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa
inhibitor, was approved by the U.S. Food and Drug Administration in
June 2017. The company is also working to advance two clinical
programs for andexanet alfa, a recombinant protein designed to
reverse the anticoagulant effect in patients treated with an oral
or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK
inhibitor in development to treat hematologic cancers. Portola's
partnered program is focused on developing selective SYK inhibitors
for inflammatory conditions. For more information,
visit http://www.portola.com and follow the Company on Twitter
@Portola_Pharma.
Investor Contact: Cara Miller Portola
Pharmaceuticals ir@portola.com
Media Contact: Patrick Ryan W2O Group
pryan@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur